Skip to main content
. 2023 Nov 18;6:1176. doi: 10.1038/s42003-023-05552-0

Fig. 4. GV101 inhibits the pro-inflammatory response of primary PBMCs and Kupffer Cells in mouse and human.

Fig. 4

PBMCs were treated with indicated doses of GV101 or KD025 1.5 h before stimulation with LPS. After 24 h, TNF, IL-23, and IL-10 secretion in supernatants was analyzed by ELISA and normalized (n = 12 except GV101 0.3 and 0.6 μM: n = 4) (a) and Western blots for the indicated proteins were performed on whole cell extracts (b). Human (c, e) or murine primary Kupffer cells (d) were treated with indicated doses of GV101 or KD025 1.5 h before stimulation with LPS and 24 h before collection of Kupffer cells supernatants for analysis of IL-6 and TNF secretion by ELISA followed by normalization (c: n = 8 except GV101/KD025 2.5 μM, n = 5 ; d: n = 4), and preparation of human Kupffer cell extracts for Western blots analysis of the indicated proteins (e). All experiments represent at least 4 independent repeats. Graphs represent mean +/− s.e.m. In (a, c, d), one way ANOVA was performed followed by multiple comparisons Sidak tests to allow two-by-two comparisons. ns: not significant, *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001. In (b, e), Western blots were quantified and normalized to the LPS-stimulated conditions, and values are indicated under the corresponding immunoblots.